Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.